MX2021007001A - Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle. - Google Patents

Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle.

Info

Publication number
MX2021007001A
MX2021007001A MX2021007001A MX2021007001A MX2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A
Authority
MX
Mexico
Prior art keywords
triloop
double
nucleic acid
stranded nucleic
acid inhibitor
Prior art date
Application number
MX2021007001A
Other languages
English (en)
Inventor
Bob Dale Brown
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of MX2021007001A publication Critical patent/MX2021007001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan moléculas inhibidoras de ácido nucleico de cadena doble que tienen una hebra de sentido con una estructura de tallo-bucle y una hebra de antisentido, donde la porción de bucle de la estructura de tallo-bucle es un tribucle; también se proporcionan métodos y composiciones para reducir la expresión de genes diana y métodos y composiciones para tratar una enfermedad de interés.
MX2021007001A 2018-12-12 2019-11-13 Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle. MX2021007001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862778759P 2018-12-12 2018-12-12
PCT/US2019/061241 WO2020123083A1 (en) 2018-12-12 2019-11-13 Double-stranded nucleic acid inhibitor molecules containing a triloop

Publications (1)

Publication Number Publication Date
MX2021007001A true MX2021007001A (es) 2021-10-13

Family

ID=71076672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007001A MX2021007001A (es) 2018-12-12 2019-11-13 Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle.

Country Status (13)

Country Link
US (1) US20220064640A1 (es)
EP (1) EP3894560A4 (es)
JP (1) JP2022521877A (es)
KR (1) KR20210127917A (es)
CN (1) CN113454221A (es)
AU (1) AU2019397247A1 (es)
BR (1) BR112021011294A2 (es)
CA (1) CA3122930A1 (es)
CL (1) CL2021001552A1 (es)
IL (1) IL283775A (es)
MX (1) MX2021007001A (es)
SG (1) SG11202106046XA (es)
WO (1) WO2020123083A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013418A (es) * 2019-05-03 2021-12-10 Dicerna Pharmaceuticals Inc Moleculas inhibidoras de acido nucleico bicatenario con cadenas de sentido acortadas.
CA3226019A1 (en) 2021-07-20 2023-01-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
US20230374522A1 (en) * 2022-04-15 2023-11-23 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating scap activity
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891216B1 (en) * 2005-05-25 2012-02-22 The University Of York Hybrid interfering rna
US20100331389A1 (en) * 2008-09-22 2010-12-30 Bob Dale Brown Compositions and methods for the specific inhibition of gene expression by dsRNA containing modified nucleotides
JP4936343B6 (ja) * 2008-10-23 2018-06-27 国立大学法人 東京大学 ｍｉｃｒｏＲＮＡの機能阻害法
WO2011132672A1 (ja) * 2010-04-19 2011-10-27 独立行政法人理化学研究所 機能性核酸の安定化法
WO2013073576A1 (ja) * 2011-11-16 2013-05-23 公立大学法人大阪市立大学 RNAi分子の活性を抑制するための核酸分子
JP7105065B2 (ja) * 2014-12-15 2022-07-22 ダイセルナ ファーマシューティカルズ， インコーポレイテッド リガンド修飾二本鎖核酸
JP6987084B2 (ja) * 2016-03-16 2021-12-22 ディセルナ ファーマシューティカルズ インコーポレイテッド β−カテニン関連疾患又は障害の治療のための組成物及び方法
DK3506909T3 (da) * 2016-09-02 2022-08-22 Dicerna Pharmaceuticals Inc 4'-phosphatanaloger og oligonukleotider omfattende samme
JP2020529197A (ja) * 2017-06-29 2020-10-08 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｈｍｇｂ１発現を阻害するための組成物及び方法
CN111971051A (zh) * 2018-04-13 2020-11-20 迪克纳制药公司 用增加tm的核苷酸修饰的双链核酸抑制剂分子

Also Published As

Publication number Publication date
BR112021011294A2 (pt) 2021-08-31
KR20210127917A (ko) 2021-10-25
IL283775A (en) 2021-07-29
CN113454221A (zh) 2021-09-28
SG11202106046XA (en) 2021-07-29
JP2022521877A (ja) 2022-04-13
EP3894560A1 (en) 2021-10-20
AU2019397247A1 (en) 2021-06-24
EP3894560A4 (en) 2022-10-19
WO2020123083A1 (en) 2020-06-18
CA3122930A1 (en) 2020-06-18
CL2021001552A1 (es) 2021-11-26
US20220064640A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
MX2021007001A (es) Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle.
MX2020010802A (es) Moleculas inhibidoras de acidos nucleicos de caracter bicatenario modificadas con nucleotidos que aumentan la tm.
EA201991369A1 (ru) Модифицированные направляющие рнк
EA201790420A1 (ru) Средства, представляющие собой модифицированную двухнитевую рнк
AU2018253578A1 (en) RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
MX2021012126A (es) Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central.
WO2016106406A3 (en) Rna agents for gst-pi gene modulation
MX2021013418A (es) Moleculas inhibidoras de acido nucleico bicatenario con cadenas de sentido acortadas.
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
ZA202108348B (en) Angiotensinogen (agt) irna compositions and methods of use thereof
MX2016013832A (es) Composiciones y metodos para tratar hemoglobinopatias.
MX2017016088A (es) Oligonucleotidos multi-conjugados definidos.
MX2016007980A (es) Acido nucleico que induce acido ribonucleico de interferencia modificado para prevenir una falla en alcanzar el objetivo, y uso del mismo.
EP3656873A3 (en) Polynucleotide enrichment and amplification using argonaute systems
MX2009002462A (es) Siarn y metodos de manufactura del mismo.
WO2017007886A3 (en) Compositions for inhibiting dux4 gene expression and uses thereof
WO2016183009A3 (en) Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna
MX2021014206A (es) Oligonucleotidos gapmer modificados y metodos de uso.
PH12021550736A1 (en) Double-stranded ribonucleic acid inhibiting expression of complement c5
CL2021001488A1 (es) Transposasa de piggybac mutada
AR083445A1 (es) siARN CONTRA LA FIBROSIS
CL2022000539A1 (es) Composiciones y métodos para inhibir la expresión del gen lect2
WO2020104649A3 (en) Novel rna compositions and methods for inhibiting angptl8
CL2022001481A1 (es) Composiciones de ácidos nucleicos
MX2022012561A (es) Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).